[Federal Register Volume 83, Number 95 (Wednesday, May 16, 2018)]
[Notices]
[Pages 22689-22690]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10414]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-1773]


Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming 
public advisory committee meeting of the Blood Products Advisory 
Committee. The general function of the Blood Products Advisory 
Committee is to provide advice and recommendations to the Agency on 
regulatory issues related to blood and products derived from blood. On 
the first day of the meeting, the Committee will provide advice 
regarding bacterial risk control strategies to enhance the safety and 
availability of platelets for transfusion. On the second day of the 
meeting, the Committee, supplemented with members from the Microbiology 
Devices Panel of the Medical Devices Advisory Committee, will function 
as a medical device panel to provide advice and recommendations to the 
Agency on classification of devices. The meeting will be open to the 
public.

DATES: The meeting will be held on July 18, 2018, from 8 a.m. to 5 p.m. 
and July 19, 2018, from 8 a.m. to 3 p.m.

ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 
Conference Center, the Great Room (Rm. 1503, sections B and C), Silver 
Spring, MD 20993-0002. Answers to commonly asked questions including 
information regarding special accommodations due to a disability, 
visitor parking, and transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.

FOR FURTHER INFORMATION CONTACT: Bryan Emery, Division of Scientific 
Advisors and Consultants, Center for Biologics Evaluation and Research 
(CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
71, Rm. 6268, Silver Spring, MD 20993-0002, 240-402-8054, 
[email protected]; or Joanne Lipkind, Division of Scientific 
Advisors and Consultants, CBER, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 6270, Silver Spring, MD 20993-0002, 240-
402-8106, [email protected]; or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area). A notice in the Federal Register about last minute modifications 
that impact a previously announced advisory committee meeting cannot 
always be published quickly enough to provide timely notice. Therefore, 
you should always check the Agency's website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting. For those unable to attend in person, the meeting will be 
also be available via webcast. The webcast will be available at the 
following link on both days: https://collaboration.fda.gov/bpac0718/.

SUPPLEMENTARY INFORMATION: 
    Agenda: On July 18, 2018, the Blood Products Advisory Committee 
will meet in open session to discuss and provide advice regarding 
bacterial risk control strategies for blood collection establishments 
and transfusion services to enhance the safety and availability of 
platelets for transfusion. The Committee will discuss the available 
strategies to control the risk of bacterial contamination of platelets 
with 5-day and 7-day dating, including bacterial testing using culture-
based devices and rapid bacterial detection devices and implementation 
of pathogen reduction technology.
    On July 19, 2018, the Committee will function as a medical device 
panel. The Committee will meet in open session to discuss and provide 
advice regarding the device reclassification from class III to class II 
of nucleic acid and serology-based point-of-care and laboratory-based 
in vitro diagnostic devices indicated for use as aids in the diagnosis 
of human immunodeficiency virus (HIV) infection. The devices that will 
be discussed by the Committee during the meeting are post-amendment 
devices that currently are classified into class III under section 
513(f)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360c(f)(1)).
    FDA intends to make background material available to the public 
approximately 2 weeks and no later than 2 business days before the 
meeting. If FDA is unable to post the background material on its 
website prior to the meeting, the background material will be made 
publicly available at the location of the advisory committee meeting, 
and the background material will be posted on FDA's website after the 
meeting. Background material is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate 
advisory committee meeting link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before July 
11, 2018. Oral presentations from the public will be scheduled between 
approximately 2:15 p.m. and 3:15 p.m. on July 18, 2018, and between 
12:30 p.m. and 1:30 p.m. on July 19, 2018. Those individuals interested 
in making formal oral presentations should notify the contact person 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before July 5, 2018. Time allotted for 
each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by July 6, 2018.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
disabilities. If you require accommodations due to a disability, please 
contact Bryan Emery

[[Page 22690]]

or Joanne Lipkin at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: May 10, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-10414 Filed 5-15-18; 8:45 am]
 BILLING CODE 4164-01-P


